Catalyst Edge · Scanner · Tickers · BMY
CATALYST DOSSIER · UPDATED 2026-09-21

$BMY

pharma · convergence 18 · conviction WATCH
Convergence Score
18
Conviction
WATCH
Signals Firing
12
Quick tools:🃏 Swipe deck🎯 Today verdict

Price & Live Quote

Loading live quote & chart…

Practice trade tools

Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.

Paper trade unavailable: missing risk-bounded frame

Reference only. Not financial advice. No brokerage order is placed.

Why $BMY?

BMY 18 WATCH pharma

Quantitative

  • Convergence score: 18 (12 signals firing YoY)

Catalysts

  • Clinical trial milestone: A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT)
  • Clinical trial milestone: A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Risks

  • Hard-to-borrow / FTD risk: Borrow rate 6.0%, distress score 30

Bear case

  • Squeeze unwind: Short interest can compress before retail catches the move — entry timing critical

Sympathy basket (cerebro)

  • ABBV via pharma r=+0.00 intra-sector (score 29)
  • MRK via pharma r=+0.00 intra-sector (score 17)
  • GILD via pharma r=+0.00 intra-sector (score 16)
  • AMGN via pharma r=+0.00 intra-sector (score 15)
  • JNJ via pharma r=+0.00 intra-sector (score 14)
  • XBI via pharma r=+0.00 intra-sector (score 12)

Signals Firing

finra_shortfinra_regshoclinicalmacroorphan_leanoge_execauto_setup_classifierauto_macro_edgar_ftsauto_macro_eia_petroleumauto_macro_nasa_powerauto_macro_ofac_sanctionsauto_macro_term_premium
Each tag is a spoke that flagged this ticker today. Weights tuned weekly against published outcomes.

Sympathy Basket

Tickers Catalyst Edge tracks as moving with this name. Cross-correlation derived from sector + score-cohort proximity.

Earnings Catalyst

No recent earnings event.

Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks and its losses — see the trust report and methodology. Not financial advice. Confirm independently before trading.

You came here for BMY. You found it after it moved, the same way everyone else did.

$99 once — every ticker on this site ranked before the open.

Tier 1 setups touched +2% intraday 49.5% of the time across 329 tracked calls. Baseline for everything else: 40.8%. That is a +8.7 point edge, measured from the NEXT OPEN — the first price you could actually pay, not the prior close. We publish the misses too: https://catalystedgescanner.com/trust/

  1. Click Become a Founding Member below.
  2. Pay $99 once — not monthly, not ever again.
  3. You keep every future release at that price. Tomorrow's ranked list lands at 3:30 AM ET, before the open.

29 of 30 founding seats left. The price goes up when they are gone.

Become a Founding Member — $99 once

One payment. Lifetime access. The free daily picks stay free — this is for people who want the full console. Not buying today? Get tomorrow's ranked list free →